- In April 2020, the U.S. Food and Drug Administration had approved the first targeted treatment for patients with cholangiocarcinoma called Pemazyre (pemigatinib). Pemazyre's approval was based on the findings of a clinical trial in which 107 patients with locally advanced or metastatic cholangiocarcinoma who had previously received therapy and had a FGFR2 fusion or rearrangement were enrolled
Frequently Asked Questions
The market is segmented based on Segmentation, By Product (5-fluorouracil (5-FU), Gemcitabine, Cisplatin, Capecitabine, Oxaliplatin), Application (Hospitals, Clinics, Others), Disease Indication (Intrahepatic Bile Duct Cancer, Extrahepatic Bile Duct Cancer), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Industry Trends and Forecast to 2031.
.
The Global Bile Duct Cancer Market size was valued at USD 214.25 USD Million in 2023.
The Global Bile Duct Cancer Market is projected to grow at a CAGR of 7.5% during the forecast period of 2024 to 2031.
The major players operating in the market include Johnson & Johnson Private Limited, Mylan N.V., Teva Pharmaceutical Industries , Sanofi, Pfizer , GlaxoSmithKline plc, AbbVie , Novartis AG, Fresenius Kabi AG, Eli Lilly and Company, F. Hoffmann-La Roche , Intercept Pharmaceuticals, Kyowa Kirin Co. , Delcath Systems , Accord Healthcare, CONMED Corporation, Boston Scientific Corporation, Bayer AG, Bristol-Myers Squibb Company, Merck & Co. .
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
